NASDAQ$CVRX
CVRx Inc · Q1 2026 earnings
Q1 2026 earnings · · After market close · Investor relations
Briefing
CVRx reported Q1 2026 revenue of $14.8M (+20% YoY) with a net loss of $13.1M and diluted loss per share of $0.50.
CVRx generated $14.8 million of revenue in Q1 2026 versus $12.3 million on higher Barostim therapy adoption. Gross profit improved to $12.9 million, but operating expenses of $25.0 million produced a net loss of $13.1 million ($0.50 per share), roughly in line with the prior-year loss.
- Revenue $14.8M (+20%).
- Gross profit $12.9M on improved unit economics.
- Net loss $(13.1)M; EPS $(0.50).
- R&D and SG&A still exceed revenue scale.
- Commercial ramp of neuromodulation therapy is key focus.
Headline financials
Revenue & EPS history
CVRx · Revenue · Quarterly
$14.8M
Forward guidance
No quantitative guidance in 10-Q; company discusses procedure growth and reimbursement milestones.
Tailwinds
- Revenue growth with expanding gross profit.
- Procedure volume trends improving.
Headwinds
- Still loss-making at operating line.
- Reimbursement and adoption pace risk.
- Cash burn until scale.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2026
-0.9%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+36.7%
Q3 2024
Best reaction
-39.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.7% | -13.3% | -29.2% | |
| Q4 2025 | -13.0% | -14.8% | +32.3% | |
| Q3 2025 | +0.8% | -3.4% | -8.5% | |
| Q1 2025 | -39.0% | -32.0% | -15.7% | |
| Q4 2024 | -7.2% | -8.4% | -28.8% | |
| Q3 2024 | +36.7% | +30.2% | +48.8% | |
| Q2 2024 | -17.5% | -14.4% | +3.3% | |
| Q1 2024 | -33.8% | -39.7% | -55.0% | |
| Q4 2023 | -1.4% | -6.1% | -19.6% | |
| Q3 2023 | -1.2% | +0.5% | +50.4% | |
| Q2 2023 | +6.2% | +5.7% | +2.3% | |
| Q1 2023 | +24.0% | +34.2% | +41.1% | |
| Q4 2022 | +3.1% | +5.9% | -24.2% | |
| Q3 2022 | +2.7% | +21.4% | +43.1% | |
| Q2 2022 | +22.1% | +24.6% | +4.6% | |
| Q1 2021 | -3.4% | -12.0% | -6.3% | |
| Q1 2022 | +12.6% | +28.5% | +14.0% | |
| Q4 2021 | +0.9% | +0.0% | -21.2% | |
| Q3 2021 | +4.8% | +4.1% | -36.5% | |
| Q2 2020 | -4.7% | -13.0% | -13.0% | |
| Q2 2021 | -5.6% | -7.5% | -15.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro